FLIXOTIDE

Flixotide Adverse Events Reported to the FDA Over Time

How are Flixotide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Flixotide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Flixotide is flagged as the suspect drug causing the adverse event.

Most Common Flixotide Adverse Events Reported to the FDA

What are the most common Flixotide adverse events reported to the FDA?

Asthma	55 (4.9%)
Dyspnoea	24 (2.14%)
Cough	22 (1.96%)
Drug Ineffective	19 (1.69%)
Product Quality Issue	19 (1.69%)
Pyrexia	17 (1.52%)
Asthenia	16 (1.43%)
Pain In Extremity	16 (1.43%)
Malaise	13 (1.16%)
Asthmatic Crisis	12 (1.07%)
Chest Pain	11 (.98%)
	Show More
Adrenal Suppression	10 (.89%)
Blood Cortisol Decreased	10 (.89%)
Pneumonia	10 (.89%)
Adrenal Insufficiency	9 (.8%)
Irritability	9 (.8%)
Peritonitis Bacterial	9 (.8%)
Pruritus	9 (.8%)
Tachycardia	9 (.8%)
Back Pain	8 (.71%)
Cardiac Failure	8 (.71%)
Drug Interaction	8 (.71%)
Fatigue	8 (.71%)
Headache	8 (.71%)
Muscular Weakness	8 (.71%)
Vomiting	8 (.71%)
Weight Decreased	8 (.71%)
Escherichia Infection	7 (.62%)
Hepatitis Cholestatic	7 (.62%)
Hypercorticoidism	7 (.62%)
Jaundice	7 (.62%)
Aphonia	6 (.53%)
Chest Discomfort	6 (.53%)
Hyperaesthesia	6 (.53%)
Hypersensitivity	6 (.53%)
Medication Error	6 (.53%)
Myalgia	6 (.53%)
Osteonecrosis	6 (.53%)
Pancreatitis Acute	6 (.53%)
Peritonitis	6 (.53%)
Rhinorrhoea	6 (.53%)
Abasia	5 (.45%)
Abnormal Behaviour	5 (.45%)
Aggression	5 (.45%)
Agitation	5 (.45%)
Anaemia	5 (.45%)
Apathy	5 (.45%)
Blood Bilirubin Increased	5 (.45%)
Bronchospasm	5 (.45%)
Disorientation	5 (.45%)
Encephalitis	5 (.45%)
Oedema Peripheral	5 (.45%)
Overdose	5 (.45%)
Retinopathy	5 (.45%)
Abdominal Pain	4 (.36%)
Accidental Overdose	4 (.36%)
Allergic Granulomatous Angiitis	4 (.36%)
Angina Pectoris	4 (.36%)
Blood Alkaline Phosphatase Increase...	4 (.36%)
Condition Aggravated	4 (.36%)
Cryoglobulinaemia	4 (.36%)
Cutaneous Vasculitis	4 (.36%)
Depressed Level Of Consciousness	4 (.36%)
Drug Administration Error	4 (.36%)
Dysgeusia	4 (.36%)
Dysphagia	4 (.36%)
Dysphonia	4 (.36%)
Ecchymosis	4 (.36%)
Fall	4 (.36%)
Gamma-glutamyltransferase Increased	4 (.36%)
General Physical Health Deteriorati...	4 (.36%)
Ill-defined Disorder	4 (.36%)
Mydriasis	4 (.36%)
Nasopharyngitis	4 (.36%)
Oral Candidiasis	4 (.36%)
Renal Tubular Disorder	4 (.36%)
Toe Amputation	4 (.36%)
Tooth Disorder	4 (.36%)
Wheezing	4 (.36%)
Adrenocortical Insufficiency Acute	3 (.27%)
Aphthous Stomatitis	3 (.27%)
Arthralgia	3 (.27%)
Atrioventricular Block Complete	3 (.27%)
Atrioventricular Block Second Degre...	3 (.27%)
Blood Corticotrophin Abnormal	3 (.27%)
Bronchiectasis	3 (.27%)
Confusional State	3 (.27%)
Conjunctival Disorder	3 (.27%)
Conjunctivitis Infective	3 (.27%)
Convulsion	3 (.27%)
Cyanosis	3 (.27%)
Disturbance In Attention	3 (.27%)
Drug Dependence	3 (.27%)
Drug Exposure During Pregnancy	3 (.27%)
Drug Intolerance	3 (.27%)
Dry Throat	3 (.27%)
Eosinophilia	3 (.27%)
Eye Disorder	3 (.27%)
Gout	3 (.27%)
Hyperhidrosis	3 (.27%)
Hyperthermia	3 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Flixotide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Flixotide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Flixotide

What are the most common Flixotide adverse events reported to the FDA?

Respiratory	80 (7.13%)
Bronchial Disorders	76 (6.77%)
Neurological	50 (4.46%)
Epidermal And Dermal Conditions	44 (3.92%)
Infections - Pathogen Unspecified	41 (3.65%)
Adrenal Gland	33 (2.94%)
Medication Errors	31 (2.76%)
Therapeutic And Nontherapeutic Effe...	30 (2.67%)
Musculoskeletal And Connective Tiss...	26 (2.32%)
Bacterial Infectious	23 (2.05%)
Body Temperature Conditions	23 (2.05%)
	Show More
Gastrointestinal Signs	22 (1.96%)
Cardiac Arrhythmias	21 (1.87%)
Product Quality Issues	21 (1.87%)
Endocrine Investigations	19 (1.69%)
Muscle	17 (1.52%)
Hepatic And Hepatobiliary	14 (1.25%)
Fungal Infectious	13 (1.16%)
Hepatobiliary	13 (1.16%)
Eye	12 (1.07%)
Bone Disorders	11 (.98%)
Headaches	11 (.98%)
Heart Failures	10 (.89%)
Mood Disorders	10 (.89%)
Movement Disorders	10 (.89%)
Oral Soft Tissue Conditions	10 (.89%)
Physical Examination Topics	10 (.89%)
Upper Respiratory Tract Disorders	10 (.89%)
Allergic Conditions	9 (.8%)
Dental And Gingival Conditions	9 (.8%)
Ocular Neuromuscular	9 (.8%)
Skin Vascular Abnormalities	9 (.8%)
Bone And Joint Injuries	8 (.71%)
Deliria	8 (.71%)
Embolism And Thrombosis	7 (.62%)
Hematology Investigations	7 (.62%)
Renal Disorders	7 (.62%)
Anemias Nonhemolytic And Marrow Dep...	6 (.53%)
Anxiety Disorders	6 (.53%)
Cardiac And Vascular Investigations	6 (.53%)
Coronary Artery	6 (.53%)
Enzyme	6 (.53%)
Exocrine Pancreas Conditions	6 (.53%)
Peritoneal And Retroperitoneal Cond...	6 (.53%)
Seizures	6 (.53%)
Therapeutic Procedures And Supporti...	6 (.53%)
Central Nervous System Infections A...	5 (.45%)
Gastrointestinal Inflammatory Condi...	5 (.45%)
Personality Disorders	5 (.45%)
Psychiatric And Behavioural Symptom...	5 (.45%)
Retina, Choroid And Vitreous Hemorr...	5 (.45%)
Skin Appendage Conditions	5 (.45%)
Vascular Inflammations	5 (.45%)
Angiedema And Urticaria	4 (.36%)
Anterior Eye Structural Change, Dep...	4 (.36%)
Autoimmune	4 (.36%)
Bone And Joint Therapeutic Procedur...	4 (.36%)
Cardiac Disorder Signs	4 (.36%)
Central Nervous System Vascular	4 (.36%)
Chemical Injury And Poisoning	4 (.36%)
Cornification And Dystrophic Skin	4 (.36%)
Glucose Metabolism Disorders	4 (.36%)
Injuries	4 (.36%)
Joint	4 (.36%)
Lower Respiratory Tract Disorders	4 (.36%)
Mental Impairment	4 (.36%)
Nephropathies	4 (.36%)
Neurological, Special Senses And Ps...	4 (.36%)
Sleep Disorders	4 (.36%)
Urinary Tract Signs	4 (.36%)
Viral Infectious	4 (.36%)
Appetite And General Nutritional	3 (.27%)
Communication Disorders	3 (.27%)
Decreased And Nonspecific Blood Pre...	3 (.27%)
Disturbances In Thinking	3 (.27%)
Electrolyte And Fluid Balance Condi...	3 (.27%)
Gastrointestinal Hemorrhages	3 (.27%)
Gastrointestinal Motility And Defec...	3 (.27%)
Increased Intracranial Pressure And...	3 (.27%)
Psychiatric	3 (.27%)
Pulmonary Vascular	3 (.27%)
Purine And Pyrimidine Metabolism	3 (.27%)
Respiratory And Pulmonary Investiga...	3 (.27%)
Toxicology And Therapeutic Drug Mon...	3 (.27%)
White Blood Cell	3 (.27%)
Depressed Mood Disorders	2 (.18%)
Encephalopathies	2 (.18%)
Eye Disorders Congenital	2 (.18%)
Gastrointestinal Vascular Condition...	2 (.18%)
Lifestyle Issues	2 (.18%)
Microbiology And Serology	2 (.18%)
Ocular Infections, Irritations And ...	2 (.18%)
Peripheral Neuropathies	2 (.18%)
Platelet	2 (.18%)
Pleural	2 (.18%)
Respiratory Disorders Congenital	2 (.18%)
Salivary Gland Conditions	2 (.18%)
Vision	2 (.18%)
Water, Electrolyte And Mineral	2 (.18%)
Bone, Calcium, Magnesium And Phosph...	1 (.09%)
Breast	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Flixotide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Flixotide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.